"Loading Stock Price & Valuation Data ..."
Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to HLVX. [ FAQ on what and how to ask] For non-HLVX questions, click the logo in the upper-right corner to return to the main page and ask there.
CEO:Dr. Robert M. Hershberg M.D., Ph.D.
Headquarter: 321 Harrison Avenue, 5th Fl., Boston, MA, United States, 02118
Industry: Biotechnology, Employees: 14
HilleVax, Inc., a clinical-stage biopharmaceutical company, develops and commercializes vaccines in the United States. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. It has a license agreement with Takeda Vaccines, Inc. to develop and commercialize HIL-214 pharmaceutical products. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
My Watchlist
